海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER - RTOG 0815
- intermediate risk prostate cancer br>MedDRA version: 12.1 Level: LLT Classification code 10026389 Term: Malignant neoplasm of prostate
- Ireland
- 2010-09-13
Authorised
- Prospective evaluation of 68-Ga-PSMA-PET and early PSA kinetics during salvage radiotherapy for personalizing the management of men with relapse of prostate cancer after radical prostatectomy.
- Patients with prostate cancer, with a PSA recurrence of ? 0.2 ng/ml after prostatectomy, and who are going to receive radiotherapy to the prostate bed. MedDRA version: 18.1 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Sweden
- 2015-12-10
Authorised
- [18F] Dihyro-testosterone(FDHT) PET/CT- A novel Imaging technique in Patients with Porgressive Prostate Cancer
- Progressive Prostate cancer br>MedDRA version: 18.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Netherlands, United Kingdom, United States
- 2015-10-23
Authorised
- A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status
- Patients with mCRPC with asymptomatic progression while on abiraterone acetate or enzalutamide MedDRA version: 19.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2016-08-17
Authorised
- Evaluation of [68Ga]PSMA PET/MRI in intermediate and high risk prostate cancer – a comparison with mpMRI, [11C]ACE PET/CT and histopathological validation
- Medium and high risk prostate cancer;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Sweden
- 2016-06-09
Authorised
- Randomized, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide
- Advanced Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, Czech Republic, Finland, France, Germany, Greece, Poland, Slovakia, South Africa, United Kingdom, United States
- 2017-12-22
Authorised
- Randomized, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide
- Advanced Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, Czech Republic, France, Germany, Greece, Hungary, Slovakia, United States
- 2018-01-16
Authorised
- Randomized, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide
- Advanced Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, Czech Republic, France, Germany, Hungary, Slovakia, United States
- 2018-01-12
Authorised
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
- Metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Slovakia, Spain, Turkey, United Kingdom, United States
- 2018-09-12
Authorised
- Research study to determine whether an investigational product Liproca® Depot single injected into the prostate is safe, tolerable and effective in treatment of localized prostate cancer for patients assigned to active surveillance and who are at high risk for disease progression – using a single blind and two-stage dose finding study design followed by an open label extension.
- Asymptomatic localized prostate cancer patients;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, Finland, Lithuania
- 2018-09-06